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The biological mechanisms underlying castration resistance of prostate cancer are not fully 
understood. In the present study, we examined the role of organic anion transporting 
polypeptides (OATPs) as importers of dehydroepiandrosterone sulfate (DHEAS) into cells to 
support growth under androgen-depleted conditions. Cell growth and mRNA expression of 
OATP genes were studied in human prostate cancer LNCaP and 22Rv1 cells under 
androgen-depleted conditions. The stimulatory effect of DHEAS on cell growth was 
investigated in LNCaP cells in which OATP1A2 had been silenced. Growth of both cell lines 
was stimulated by DHEAS and the effect was attenuated by STX64, an inhibitor of steroid 
sulfatase which can covert DHEAS to DHEA. OATP1A2 mRNA expression was increased 
most prominently among various genes tested in LNCaP cells grown in androgen-depleted 
medium. Similar results were obtained with 22Rv1 cells. Furthermore, the characteristics of 
[3H]DHEAS uptake by LNCaP cells were consistent with those of OATP-mediated transport. 
Knockdown of OATP1A2 in LNCaP cells resulted in loss of the DHEAS sensitivity of cell 
growth. Our results suggest that enhanced OATP1A2 expression is associated with adaptive cell 
growth of prostate cancer cells under androgen-depleted conditions. Thus, OATP1A2 may be a 







Gonadal androgens play a critical role in protein synthesis and cell survival in prostate tumors 
[1]. Therefore, androgen deprivation therapy (ADT) to remove gonadal testosterone or to 
antagonize androgen receptors is currently a mainstream treatment for prostate cancer. Once the 
disease progresses to castration-resistant prostate cancer (CRPC), it no longer responds to 
androgen deprivation therapy. CRPC tumor progression is considered to involve enhanced 
androgen receptor (AR) function, mainly due to AR gene amplification/overexpression [2], 
stabilization of AR protein and increased sensitivity of AR to androgens [3], and constitutive, 
ligand-independent activation [4].  
 
The organic anion transporter polypeptide (OATP/SLCO) family members generally mediate 
Na+-independent transport of amphipathic organic anion compounds, including bile salts, 
steroid conjugates, thyroid hormones, and oligopeptides [5, 6]. The physiological roles of these 
transporters are not yet fully understood, but there is compelling evidence that certain members 
of the OATP family promote cell proliferation and survival of human malignant tissues. We 
have previously shown that transport of estrone 3-sulfate via OATPs sustains the growth of 
hormone-dependent human breast cancer cells [7, 8], because estrone-3-sulfate can be 
hydrolyzed by steroid sulfatase (STS) to estrone and eventually estradiol. We recently showed 
that OATP1B3 contributes to estrone 3-sulfate uptake in estrogen receptor-positive human 
breast cancer MCF-7 cells [9]. In addition to estrone 3-sulfate, these OATPs translocate 
dehydroepiandrosterone sulfate (DHEAS) [10, 11]. DHEAS is a thousand fold more abundant 
than testosterone in human serum [12], and is essentially unaffected by ADT. DHEAS is 
hydrolyzed to DHEA by STS [13], and DHEA can be converted to androstenedione in prostate 
cancer [14], resulting in activation of AR function [15]. More recently, clinical observations 
have suggested that several OATPs are upregulated in castration-resistant metastatic prostate 
tumor tissues derived from human patients [16]; however, it remains unclear whether OATPs 
play a role in prostate cancer cell survival under androgen-depleted conditions. We 
hypothesized that increased expression of OATPs does contribute to cell survival of 
androgen-dependent prostate cancer cells under androgen deprivation, by providing the cells 
with an increased supply of DHEAS as a precursor of active androgen. 
 
In the present study, we investigated the expression of functional OATPs in, and the growth of, 
androgen-dependent prostate cancer cells. Among the OATP family members tested, OATP1A2 
was found to be remarkably upregulated in AR-positive human prostate cancer cells cultured 
under androgen-depleted conditions. We propose that enhanced expression of OATP1A2 in 
these cells plays a role in progression of prostate cancer by increasing the availability of 
DHEAS as a precursor of active androgen, under conditions of androgen depletion. 
 
2. Materials and methods 
 
2.1. Materials 
DHEAS, dihydrotestosterone (DHT), and [3H]DHEAS sodium salt (3.50 TBq/mmol) were 
purchased from Tokyo Chemical Industry (Tokyo, Japan), Wako Pure Chemical Industries 
(Osaka, Japan), and PerkinElmer Life Science (Boston, MA), respectively. Human prostate 
cancer LNCaP and 22Rv1 cell lines were purchased from American Type Culture Collection 
(Manassas, VA). 
 
2.2. Cell culture and growth assays 
LNCaP and 22Rv1 cells were cultured in RPMI1640 (Wako Pure Chemical Industries) with 
penicillin (100 units/mL, Nakalai Tesque, Kyoto, Japan), streptomycin (100 μg/mL, Wako Pure 
Chemical Industries) and 10% fetal bovine serum (FBS, Invitrogen). Cells were cultured in a 
humidified atmosphere containing 5% CO2 at 37oC. For the cell growth assay, cells were 
cultured in RPMI1640 with penicillin (100 units/mL), streptomycin (100 μg/mL) supplemented 
with FBS or charcoal-stripped FBS (CSS, Invitrogen) in the presence or absence of androgen 
and/or STX64 (also known as 667 coumate or 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta-
[c]chromen-3-yl sulfamate, Sigma Aldrich, St. Louis, MO), which is a tricylic coumarin-based 
sulfamate that inhibits steroid sulfatase. The growth-stimulatory effect of androgens, including 
DHEAS, was evaluated by measuring cell growth after cells were plated at a density of 1.5 to 
2.4 × 104 cells/cm2 on a 96-well tissue culture plate. In general, once cells became attached to 
the plate, a test androgen or DMSO (at 0.1% of the final concentration) was added to the well, 
and cell growth was monitored for up to 9 days by means of sulforhodamine B (SRB, Sigma 
Aldrich) assay as previously described [17].  
 
2.3. Gene expression profiling assay 
LNCaP cells were cultured in RPMI1640 with penicillin (100 units/mL), streptomycin (100 
μg/mL) and 10% CSS for 6 days. Then, total RNA was prepared using Isogen reagent (Nippon 
Gene, Tokyo, Japan). Microarray experiments were performed and data were analyzed according 
to the manufacturer's instructions (Agilent Technologies, Santa Clara, CA). In brief, 300 ng of 
total RNA was subjected to linear amplification and Cy3 labeling using the Low RNA Input 
Linear Amplification Kit (Agilent Technologies), and then hybridized to a 44-K Whole Human 
Genome Microarray (Agilent Technologies). Data were extracted using Feature Extraction 
software (version 9.5.3) and analyzed using GeneSpring GX software (version 11.0). 
 
2.4. Reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was prepared from cells using Isogen reagent (Nippon Gene). mRNA expression of 
OATP1A2, OATP1B1, OATP1B3, OATP2B1, OAT2, OAT3, and OAT4 was measured by 
quantitative RT-PCR (qRT-PCR), using Brilliant SYBR Green QPCR Master Mix (Agilent 
Technologies). The fold change in mRNA expression of transporter genes was normalized to 
hypoxanthine guaninephosphoribosyl-transferase 1 (HPRT1) using the 2-ΔΔ threshold cycles 
(Ct) method [18]. Primer sequences specific to transporter genes tested are listed in Table 1. 
 
2.5. [3H]DHEAS cellular uptake assay 
Intracellular accumulation of DHEAS was evaluated by means of uptake assays as described 
previously [17]. Briefly, cells were plated at a density of 1.0 x105 cells/cm2 on a 24-well 
tissue-culture plate in culture medium supplemented with 10% FBS or CSS in the absence or 
presence of DHT (1 nM) two days before assay containing 0.1% DMSO of the final 
concentration. The assay was initiated by adding transport buffer (125 mM NaCl, 4.8 mM KCl, 
5.6 mM D-glucose, 1.2 mM CaCl2, 1.2 mM KH2PO4,1.2 mM, MgSO4, and 25 mM HEPES, 
adjusted to pH 7.4) containing 0.5 μCi/mL [3H]DHEAS (10 nM) with or without inhibitors at 
37oC. Sodium dependence of uptake was evaluated by replacing Na+ with Li+, K+ or 
N-methylglucamine (NMG+). At the end of the assay, cells were washed with ice-cold transport 
buffer and solubilized in 1% (v/v) Triton X-100 (Wako Pure Chemical Industries). The 
radioactivity in the resultant cell lysate was measured using a liquid scintillation counter (Aloka, 
Tokyo, Japan). Intracellular [3H]DHEAS accumulation was normalized by protein content 
determined with a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA), and is shown as the ratio 
of accumulation to the initial concentration of DHEAS, i.e., cell-to-medium (C/M) ratio 
(μL/mg). 
 
2.6. Western blot 
To determine protein expression of OATP1A2, cells were collected and lysed in RIPA buffer 
(150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM 
Tris at pH 8.0) by sonication. A 50 μg aliquot of total cell lysate was subjected to SDS 
polyacrylamide gel electrophoresis, and then electrotransferred onto a polyvinylidene difluoride 
membrane (Millipore, Billerica, MA). The blots were probed with anti-human OATP1A2 rabbit 
polyclonal antibody (Assay Biotechnology Company, San Francisco, CA) at 1 to 500 dilution or 
with anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) rabbit monoclonal antibody 
(Cell Signaling Technology, Danvers, MA) at 1 to 2000 dilution, followed by appropriate 
secondary antibodies conjugated to horseradish peroxidase (Amersham Pharmacia Biotech, 
Piscataway, NJ).  
 
2.7. Construction of OATP1A2-Transfected LNCaP Cells 
LNCaP cells were transfected with pcDNA3.1/OATP1A2 or pcDNA3.1 alone (Invitrogen), and 
then selected with 800 μg/mL of G418 (Wako Pure Chemicals). Enhanced OATP1A2 
expression was verified by uptake study of [3H]DHEAS (0.5 μCi/mL) for up to 5 min and 
Western blotting using anti-human OATP1A2 rabbit IgG. 
 
2.8. OATP1A2 knockdown in LNCaP cells 
To develop prostate cancer cell lines with knockdown of OATP1A2, double-stranded DNA 
containing a hairpin sequence for the targeted site (5’–tattctttggctgccatacct-3’) and 
(5’-aagtgtcatctacctggtgaa-3’) of OATP1A2 mRNA was inserted into the microRNA-adapted 
vector pcDNA 6.2-GW/EmGFP-miR (Invitrogen). Knockdown of OATP1A2 was performed 
using the BLOCK-iT Pol II miR RNAi expression vector kit according to the manufacturer's 
instructions (Invitrogen). The pcDNA6.2-GW/EmGFP-miR-negative control plasmid contains 
an oligonucleotide not related to OATP1A2, which serves as a negative control. LNCaP cells 
were transfected with these plasmid DNAs using LipofectAMINE 2000 reagent (Invitrogen). 
Two days later, selection of transfected cells was started with blasticidin (2 μg/mL, Invitrogen). 
After about 3 weeks, blasticidin-resistant and EmGFP-positive cells were used for the 
proliferation studies and subjected to RT-PCR analysis. 
 
3. Results 
3.1. DHEAS-induced cell growth and PSA expression in androgen receptor-positive prostate 
cancer cells  
In order to determine whether DHEAS can stimulate cell growth of androgen receptor-positive 
human prostate cancer LNCaP cells, cell growth was measured in androgen-depleted medium. 
The cell growth was stimulated by DHEAS in a concentration-dependent manner. At a 
physiologically relevant serum concentration of DHEAS (5 μM), the growth increased about 
174% compared to that in the absence of DHEAS, corresponding to about half of the effect of 
DHT, an active androgen, at 1 nM (Figure 1A). DHEAS also exhibited a stimulatory effect on 
cell growth of 22Rv1 cells (16% ± 1.82 % on Day 9) compared to that in the absence of 
DHEAS (data not shown). The stimulatory effect observed in LNCaP cells was significantly 
attenuated in the presence of STX64, a specific inhibitor of STS (Figure 1B), suggesting that 
activation of cell growth by DHEAS requires its conversion to DHEA mediated by STS. 
Expression of STS showed no change in LNCaP cells grown in normal and CSS-containing 
medium (Figure 1C). In parallel, DHEAS induced mRNA expression of prostate specific 
antigen (PSA) in LNCaP cells, reflecting the effect of DHEAS on the cell growth (Figure 1D).  
 
3.2. Alteration in organic anion transporter levels in androgen receptor-positive prostate 
cancer cells 
DHEAS is an organic anion at physiological pH, and its uptake requires carrier-mediated 
transport across plasma membranes. We therefore performed a microarray analysis to compare 
the gene expression profiles of transporters that might be involved in DHEAS uptake between 
LNCaP cells grown in normal and androgen-depleted culture medium. Table 2 summarizes the 
genes whose expression altered by more than 1.5 times under the androgen-depleted condition; 
there were significant increases in several OATP genes, including OATP5A1, 1A2, and 1B1. 
This was confirmed by qRT-PCR (Figure 2A). OATP1A2 mRNA expression was increased 
most markedly among the genes tested, and was 3.6- and 6.4-fold greater in LNCaP cells 
cultured in CSS-containing medium on Days 3 and 7, respectively, than on Day 1; however, no 
such increase was observed in LNCaP cells cultured for 7 days in normal medium (data not 
shown). Similarly, mRNA expression levels of OATP2A1 and 1B1 on Day 7 were increased 
3.4- and 7.4-fold, respectively (Figure 2A). Table 3 summarizes the fold difference in mRNA 
expression of OATP genes tested on Days 3 and 7. Western blotting analysis indicated a 
time-dependent increase of OATP1A2 protein expression (Figure 2B). More interestingly, the 
stimulation of OATP1A2 mRNA expression under the androgen-depleted condition was almost 
completely abolished by the addition of DHT (Figure 2C), suggesting that OATP1A2 gene 
transcription is negatively regulated by androgens. Expression of DHEAS transporters was also 
studied in 22Rv1 cells grown in both normal and androgen-depleted medium, and qualitative 
PCR results are shown in Figure 2D. Significant mRNA expression of OATP2A1, 2B1, 3A1, 
4A1 and SLC10A4 was detected in 22Rv1 cells as well. Similarly, transcription of OATP1A2 
and SLC10A4 appeared to be upregulated when the medium was deprived of androgen. Further 
qRT-PCR analysis showed that OATP1A2 mRNA expression was increased 3.7-fold in 22Rv1 
cells, confirming DHT-mediated negative regulation of the transcription (Figure 2E). 
  
3.3. Enhanced cellular uptake of DHEAS under androgen deprivation 
To study the contribution of OATPs to cellular uptake of DHEAS in LNCaP cells, intimal 
uptake of [3H]DHEAS was measured in the absence or presence of several inhibitors of organic 
anion transport systems. The uptake was significantly reduced in the presence of unlabeled 
DHEAS, estrone 3-sulfate and BSP, which are inhibitors of OATPs, but inhibitors of OAT 
(salicylate and p-aminohippouric acid) and organic cation transporter inhibitors 
(tetra-ethylammonium and 1-methyl-4-phenylpyridinium) had no effect (Figure 3A). The 
uptake was tolerant of Na+ replacement with Li+, K+ and NMG+ (Figure 3B). Accordingly, 
[3H]DHEAS uptake by LNCaP cells has the characteristics of OATP-mediated transport. 
Furthermore, [3H]DHEAS uptake was significantly enhanced in LNCaP cells cultured with 
CSS-containing medium for 2 days, but addition of DHT (1 nM) to the medium significantly 
decreased the uptake, implying that cellular uptake of DHEAS is regulated by OATPs whose 
expression is negatively regulated by androgen, such as OATP1A2 (Figure 3C). 
 
3.4. Contribution of OATP1A2 to DHEAS-induced cell growth in LNCaP cells 
To further examine the role of OATP1A2 in DHEAS-induced growth of prostate cancer cells, 
growth of OATP1A2-transfected LNCaP cells was examined in CSS-containing medium in the 
absence or presence of 5 μM DHEAS. In the presence of DHEAS, growth of 
OATP1A2-transfected cells was stimulated by 41 %, whereas that of cells transfected with an 
empty-vector plasmid increased by only 11 %. Furthermore, the stimulatory effect of DHEAS 
was evaluated in LNCaP cell lines in which OATP1A2 had been silenced, designated as KD16 
and KD34, compared with control cell lines (C3 and C9). As shown in Figure 4A, mRNA 
expression of OATP1A2 in KD16 and KD34 cells was almost completely knocked down. The 
effect of DHEAS on growth of the cell lines tested was normalized with respect to that in the 
absence of DHEAS (1.00) on Day 3 through Day 7 (Figure 4B). In the two control cells lines, 
DHEAS significantly stimulated cell growth with the highest stimulation on Day 5 or 6, even 
though there were differences in degree of stimulation, whereas there was no statistically 
significant effect on growth of KD16 and KD34 cells during the experiments (p-value of 0.207 
for KD16 and 0.056 for KD34 by one-way ANOVA). The finding that growth of 
OATP1A2-knockdown cells was insensitive to DHEAS suggests that OATP1A2 plays a 
predominant role in DHEAS-induced cell growth under androgen-depleted conditions.   
 
4. Discussion 
Our present findings indicate that OATP-mediated DHEAS transport plays a major role in 
survival and proliferation of androgen-receptor-positive prostate cancer cells under conditions 
of androgen depletion. In other words, enhanced import of DHEAS mediated by increased 
expression of OATPs, most likely predominantly OATP1A2, can be utilized to provide an 
alternative source of androgen under conditions of androgen depletion, allowing prostate cancer 
cells scope to acquire castration resistance, because the high serum concentration of DHEAS is 
little altered during the course of ADT. 
 
To date, little is known about the role of OATPs in prostate cancer cells, although enhanced 
expression of OATPs in prostate tumors has been reported [16, 19]. Among them, OATP1B3 
may be an important player for driving cell proliferation of prostate cancer cells, because it 
facilitates testosterone uptake into cells [19]. A more recent study with patient-derived prostate 
tumor specimens indicated that mRNA expression of six SLCO genes, including SLCO1B3 and 
2B1, was enhanced several-fold in CRPC metastases, compared to untreated prostate cancer, 
implying their association with prostate cancer-specific motility [16]. In the present study, we 
observed remarkable upregulation of OATP1A2 mRNA expression, as well as significant 
increases of OATP2A1 and 1B1 on Day 7 in CSS-containing culture medium, whereas 
expression of OATP2B1 and OATP1B3 was increased only moderately and slightly, 
respectively (Figure 2). We also found a stimulatory effect of DHEAS on growth of LNCaP and 
22Rv1 cells (Figure 1); therefore, we focused here on DHEAS transport by OATPs, even 
though several other substrates are also commonly transported by the OATPs whose expression 
is enhanced. 
 
Several classes of SLC transporters have been shown to mediate DHEAS uptake, including 
OATP1A2, 1B1, 1B3, and 2B1 [10, 11], OAT2, 3, and 4 [20-22], and Na+-dependent 
taurocholate cotransporting polypeptide (NTCP) [23]. Hence, we conducted gene expression 
profiling of human prostate cancer LNCaP cells cultured under androgen-depleted conditions 
(Table 2A and Table 3). Microarray analysis suggests that OATP molecules are preferentially 
upregulated in LNCaP cells cultured in the absence of androgens, and this idea was supported 
by evidence that the functional characteristics of DHEAS transport in LNCaP cells resemble 
those of OATP-mediated transport (Figure 3A and 3B). Among several OATPs whose 
expression is enhanced by androgen deprivation, OATP1A2 showed the greatest increase in 
expression, and interestingly, its expression is negatively regulated by androgen signaling 
(Figure 2C). The increase of OATP1A2 mRNA was confirmed by Western blotting, showing two 
distinct bands around 75 and 100 kDa. This result agrees with two bands previously shown for 
OATP1A2 expressed in breast cancer cells in Western blotting, suggesting that OATP1A2 is 
glycosylated [24]. We found that expression of OATP1A2 was increased in LNCaP and 22Rv1 
cells cultured under conditions of hormone deprivation, and the increase was consistent with the 
increase of initial uptake of DHEAS in LNCaP cells (Figure 3C). Ligand-bound nuclear 
hormone receptors activate transcription in the classical mode of receptor action, by binding to 
the regulatory sequence of the target gene promoter in dimer form. However, they also silence 
gene expression in various ways, such as through recruiting co-repressor, changing chromatin 
structure and accessibility, or inhibiting signaling pathways via cross-talk. For instance, 
androgen receptor has been shown to act as a ligand-dependent trans-repressor of activator 
protein-1 (AP-1) activity, resulting in attenuation of AP-1-activated gene expression [25]. The 
proximal promoter region of OATP1A2 has been characterized, and contains active 
cis-elements for several hepatocyte nuclear factors, a TAATAT box, and a putative AP-1 
binding site [26]; it was therefore speculated that androgen-dependent negative regulation may 
be due to inhibition of AP1 by ligand-bound androgen receptor in LNCaP cells. Further study is 
needed to clarify the precise mechanism of repression of OATP1A2 expression by active 
androgens.   
 
Because DHEAS is an inactive precursor of DHEA, it has to be activated by desulphation. It 
was reported that DHEAS is hydrolyzed by STS in LNCaP cells [27] and the expression of STS 
is increased in prostate cancer cells, compared to non-malignant prostate tissues, as determined 
by immunohistochemical staining [28]. In the present study, expression of STS mRNA was 
detected in LNCaP cells, and this expression was not affected under androgen-depleted 
conditions (Figure 1C). Furthermore, cell growth of LNCaP cells was significantly reduced in 
the presence of STX64 (Figure 1B), while PSA mRNA expression in LNCaP cells was 
increased in the presence of DHEAS (Figure 1D). These results suggest that DHEAS undergoes 
metabolism at least to DHEA, mediated by STS. DHEA thus generated may have a weak 
androgenic potential to activate AR directly, but is more likely converted to T or DHT via 
3b-hydroxysteroid dehydrogenase (3bHSD), since cell proliferation of LNCaP cells in the 
presence of DHEA was reported to be suppressed by inhibition of 3bHSD [15]. Although 
DHEA is present in human serum (~ 5 nM), the DHEAS concentration in serum (3 ~ 5 μM) is 
almost a thousand fold greater [12]; therefore, DHEAS may be taken up by prostate cancer cells 
via OATPs as a source of DHEA to compensate for the shortage of androgen in serum. This 
notion is supported by the experimental finding that knockdown of OATP1A2 in LNCaP cells 
resulted in loss of the cell growth response to DHEAS (Figure 4). Thus, concomitant use of a 
blocker of OATP1A2 may be pharmacologically important to more efficiently eradicate prostate 
cancer cells during the course of ADT. It is also noteworthy that, among non-synonymous 
polymorphisms which have been reported in SLCO1A2 gene, decreased transport of estrone 
sulfate was reported in c.767A>C (rs11568563, E172D) and c.655A>T (rs45502302, N135I) 
[29, 30]. Therefore, the efficacy of ADT might be affected in prostate cancer patients with these 
genotypes, of which c.767A>C is relatively frequent in Europeans and Americans (5.3%).  
 
5. Conclusion 
In conclusion, our results indicate that OATP1A2 plays a role in the growth of prostate cancer 
cells under androgen-depleted conditions by supplying DHEAS as an alternative source of 
androgen, so that the cells can survive to acquire castration resistance. This is a novel 
mechanism underpinning the progression of advanced prostate cancer to the castration-resistant 
state. Hence, OATPs (especially OATP1A2) may be a pharmacological target for more 
effective treatment of prostate cancer. In other words, pharmacological inhibition of 
OATP1A2-mediated influx transport of DHEAS in conjunction with ADT might be effective to 
improve the prognosis of prostate cancer patients. 
 
Acknowledgments 
This research was carried out with the support of a Grant-in-Aid for Scientific Research 
(KAKENHI) to T. N. (23590176) from the Japan Society for the Promotion of Science.  
 
Conflict of interest  





[1] Brawer MK. Hormonal therapy for prostate cancer. Rev Urol 2006;8:S35-S47. 
[2] Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. 
Amplification and overexpression of androgen receptor gene in hormone-refractory 
prostate cancer. Cancer Res 2001;61:3550-5. 
[3] Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation 
of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N 
Eng J Med 1995;332:1393-8. 
[4] Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat 
Rev Cancer 2001;1:34-45. 
[5] Tamai I, Nezu J-i, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification 
and characterization of novel members of the human organic anion transporter (OATP) 
family. Biochem Biophys Res Commun 2000;273:251-60. 
[6] Nakanishi T, Tamai I. Solute carrier transporters as targets for drug delivery and 
pharmacological intervention for chemotherapy. J Pharm Sci 2011;100:3731-50. 
[7] Nozawa T, Suzuki M, Takahashi K, Yabuuchi H, Maeda T, Tsuji A, et al. Involvement of 
estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J 
Pharmacol Exp Ther 2004;311:1032-7. 
[8] Nozawa T, Suzuki M, Yabuuchi H, Irokawa M, Tsuji A, Tamai I. Suppression of cell 
proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast 
cancer cells. Pharm Res 2005;22:1634-41. 
[9] Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, et al. Uptake 
transporter organic anion transporting polypeptide 1B3 contributes to the growth of 
estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 2010;122:180-5. 
[10] Kullak-Ublick G-A, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, et al. 
Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human 
liver and brain. FEBS Lett 1998;424:173-6. 
[11] Cui Y, König J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its 
conjugates by the human organic anion transporter SLC21A6. J Biol Chem 
2001;276:9626-30. 
[12] Labrie F, Bélanger A, Cusan L, Gomez J-L, Candas B. Marked decline in serum 
concentrations of adrenal C19 sex steroid precursors and conjugated androgen 
metabolites during aging. J Clin Endocrinol Metab 1997;82:2396-402. 
[13] Reed MJ, Purohit A, Woo LWL, Newman SP, Potter BVL. Steroid sulfatase: Molecular 
biology, regulation, and inhibition. Endocrine Reviews 2005;26:171-202. 
[14] Longcope C. Metabolism of dehydroepiandrosterone. Ann N Y Acad Sci 
1995;774:143-8. 
[15] Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 3β-Hydroxysteroid 
dehydrogenase is a possible pharmacological target in the treatment of 
castration-resistant prostate cancer. Endocrinology 2010;151:3514-20. 
[16] Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, et al. 
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of 
genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer 
Epidemiol Biomarkers Prev 2011;20:619-27. 
[17] Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I, Nakanishi T. Impact of system L 
amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: A 
possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. 
Biochem Pharmacol 2010;80:811-8. 
[18] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2-[delta][delta]CT method. Methods 2001;25:402-8. 
[19] Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, et al. Effect of 
SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients 
with androgen-independent prostatic cancer. Clinical Cancer Research 2008;14:3312-8. 
[20] Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport 
mechanism and substrate specificity of human organic anion transporter 2 (hOat2 
[SLC22A7]). J Pharm Pharmacol 2005;57:573-8. 
[21] Cha SH, Sekine T, Fukushima J-i, Kanai Y, Kobayashi Y, Goya T, et al. Identification 
and characterization of human organic anion transporter 3 expressing predominantly in 
the kidney. Mol Pharmacol 2001;59:1277-86. 
[22] Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, et al. Molecular cloning and 
characterization of multispecific organic anion transporter 4 expressed in the placenta. J 
Biol Chem 2000;275:4507-12. 
[23] Geyer J, Fernandes CF, Döring B, Burger S, Godoy JR, Rafalzik S, et al. Cloning and 
molecular characterization of the orphan carrier protein Slc10a4: Expression in 
cholinergic neurons of the rat central nervous system. Neuroscience 2008;152:990-1005. 
[24] Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB. Interplay between 
the nuclear receptor pregnane X receptor and the uptake transporter organic anion 
transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. 
Cancer Res 2008;68:9338-47. 
[25] Shemshedini L, Knauthe R, Sassone-Corsi P, Pornon A, Gronemeyer H. Cell-specific 
inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear 
receptors. EMBO J 1991;10:3839-49. 
[26] Kullak-Ublick G, Beuers U, Fahney C, Hagenbuch B, Meier PJ, Paumgartner G. 
Identification and functional characterization of the promoter region of the human 
organic anion transporting polypeptide gene. Hepatology 1997;26:991-7. 
[27] Selcer KW, Kabler H, Sarap J, Xiao Z, Li P-K. Inhibition of steryl sulfatase activity in 
LNCaP human prostate cancer cells. Steroids 2002;67:821-6. 
[28] Nakamura Y, Suzuki T, Fukuda T, Ito A, Endo M, Moriya T, et al. Steroid sulfatase and 
estrogen sulfotransferase in human prostate cancer. Prostate 2006;66:1005-12. 
[29] Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, et al. 
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2). J 
Biol Chem 2005;280:9610-7. 
[30] Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, et al. Interaction of 
Methotrexate with Organic-Anion Transporting Polypeptide 1A2 and Its Genetic 





Gene specific primers for RT-PCR  
 
Symbol  




(bp) Gene Protein 
SLCO1A2 OTAP1A2  Fw AAGACCAACGCAGGATCCAT 20 101 
  Rev GAGTTTCACCCATTCCACGTACA 23 
SLCO2A1 OATP2A1 Fw CTGTGGAGACAATGGAATCGAG 22 147 
  Rev CACGATCCTGTCTTTGCTGAAG 22 
SLCO1B1 OATP1B1  Fw GAATGCCCAAGAGATGATGCTT 22 154 
  Rev AACCCAGTGCAAGTGATTTCAAT 23 
SLCO2B1 OATP2B1 Fw CGCACTCACTGATTCCTACACATT 24 278 
  Rev AAGCCATACCATCACTCATTACAC 24 
SLCO5A1 OATP5A1 Fw TCATTGGAAYGGGCTCCAC 19 213 
  Rev TGAAACGAGGGTCATTCTGG 20 
SLCO1B3 OATP1B3  Fw GTCCAGTCATTGGCTTTGCA 20 111 
  Rev CAACCCAACGAGAGTCCTTAGG 22 
SLCO3A1 OATP3A1  Fw TACGACAATGTGGTCTACCGATAC 24 309 
  Rev CAGAGTTCAGCCCTCCTTTAGTCA 24 
SLCO4A1 OATP4A1 Fw GCACCAGTTGAAGGACAGC 19 88 
  Rev GAGCCAGATGGAGAGAGG 18 
STS  Fw GGAGAAATTCATGGCGGAAG 20 134 
  Rev GTGGGCTCATCAATCTTCTGG 21 
KLK3 PSA Fw AGAGGAGTTCTTGACCCCAAAG 22 182 
  Rev GCACACCATTACAGACAAGTGG 22 
HPRT1 HPRT Fw TGACACTGGCAAAACAATGCA 21 194 








Alterations of transporter gene expression in LNCaP cells under androgen-depleted conditions, 
as determined by microarray assay 
 
Gene Protein Major substrate Fold change 
SLC10A4 P4 Bile acid 4.85 
SLCO5A1 OATP5A1 Organic anion 4.39 
SLCO1A2 OATP1A2 Organic anion 3.87 
SLCO1B1 OATP1B1 Organic anion 2.47 
SLCO2B1 OATP2B1 Organic anion 1.74 
SLC22A6 OAT1 Organic anion 0.654 
SLC10A1 NTCP Taurocholate 0.606 
SLC22A13 OAT10 Organic anion 0.486 




Quantitative changes in mRNA expression of OATP transporters in LNCaP cells under 
androgen-depleted condition, as determined by qRT-PCR 
 
Protein name 
Fold change relative to Day 1 
Day 3 Day 7 
OATP1A2 3.6 ± 0.20* 6.4 ± 1.2* 
OATP2A1 1.7 ± 0.31* 3.4 ± 0.23* 
OATP5A1 0.96 ± 0.30* 0.93 ± 0.36 
OATP3A1 0.49 ± 0.15* 2.3 ± 1.2 
OATP1B1 1.9 ± 0.59* 7.4 ± 2.9* 
OATP1B3 0.72 ± 0.20 0.80 ± 0.37 
OATP2B1 1.7 ± 0.25* 2.2 ± 0.38* 
OATP4A1 1.0 ± 0.21 0.98 ± 0.88 
All data are presented as mean ± S.E. (n=5 or 6). * indicates a significant difference from day 1 







Figure 1: DHEAS-induced cell proliferation and PSA expression in LNCaP cells. (A) Growth 
of LNCaP cells was monitored by means of SRB assay for up to 7 days. LNCaP cells cultured 
in RPMI1640 with 10% CSS for 7 days were seeded at 8,000 cells each in the presence or 
absence of androgen. Each bar represents the mean ± S.E. (n=6), and * indicates a significant 
difference from the control (p < 0.05) by Student’s t-test. (B) Effect of STS inhibitor STX64 (10 
μM) on stimulation of LNCaP cell growth by DHEAS. LNCaP cells cultured in RPMI1640 with 
5% CSS for up to 9 days were seeded at 8,000 cells. Their growth was monitored in the absence 
(open, control) and presence (closed) of DHEAS (5 μM) with (square) or without (circle) 
STX64 (10 μM). Experiments were done in quadruplicate and repeated at least twice. Each 
point represents the mean ± S.E. (n = 4), and * indicates a significant difference from the control 
(p < 0.05) by Student’s t-test. (C) Expression change of STS or (D) PSA in LNCaP cells was 
measured by qRT-PCR. LNCaP cells were cultured in RPMI1640 supplemented with 10% FBS 
or 10% CSS in the presence or absence of androgen. Each bar represents the mean ± S.E. (n=3), 
and * indicates a significant difference from the control (p < 0.05) by Student’s t-test. 
 
Figure 2: Changes of expression of organic anion transporters in androgen receptor-positive 
prostate cancer cells. (A) mRNA expression of OATP transporter genes in LNCaP cells was 
measured by qRT-PCR. LNCaP cells were cultured in RPMI1640 with 10% CSS for up to 6 
days. Each bar represents the mean ± S.E. (n=5 or 6), and * indicates a significant difference 
from the control (p < 0.05) by Student’s t-test. (B) OATP1A2 protein expression was measured 
by Western blotting. LNCaP cells were cultured in RPMI1640 supplemented with 10 % CSS in 
the presence or absence of DHT (1 nM) for up to 6 days. A typical Western blot showing 
increased OATP1A2 expression is presented. Each bar (sum of the two bands shown) represents 
the mean value of densitometric analysis of three individual blots ± S.E. (n=3), and * indicates a 
significant difference from the control (p < 0.05) by Student’s t-test. (C) Effect of DHT (1 nM) 
on mRNA expression of OATP1A2 in LNCaP and (E) 22Rv1 cells cultured in RPMI1640 
supplemented with 10% FBS or 10% CSS in the presence or absence of DHT (1 nM) for 2 days. 
Each bar represents the mean ± S.E. (n=3). * and † indicate a significant difference from the 
expression of OATP1A2 in LNCaP cultured in RPMI1640 supplemented with 10% FBS or 10% 
CSS (p < 0.05) by Student’s t-test, respectively. (D) mRNA expression of organic anion 
transporters and HPRT in 22Rv1 cells was determined by RT-PCR. 22Rv1 cells were cultured 
in RPMI1640 supplemented with 10% FBS or 10% CSS for 2 days. PCR products were 
visualized on 2% agarose gel.  
 
Figure 3: Characterization of [3H]DHEAS uptake by LNCaP cells. (A) Cellular uptake of 
[3H]DHEAS (10 nM) was measured in the presence or absence of the indicated compounds at 
pH 7.4 for 5 min in LNCaP cells cultured in RPMI1640 with 10% CSS for 2 days. Each bar 
represents the mean ± S.E. (n=3 or 4), and * indicates a significant difference from the control (p 
< 0.05) by Student’s t-test. E3S; Estrone 3-sulfate, BSP; bromosulfophthalein, TCA; 
taurocholate, PRO; probenecid, SAL; salicylate, PAH; p-aminohippurate, TEA; 
tetra-ethylammonium, MPP+; 1-methyl-4-phenylpyridinium. (B) Cellular uptake of [3H]DHEAS 
(10 nM) was measured in the presence or absence of extracellular Na+. Extracellular Na+ was 
replaced with K+, Li+, or N-methylglucamine (NMG+) at pH 7.4 for 5 min in LNCaP cells 
cultured in RPMI1640 with 10% CSS for 2 days. Each value represents the mean ± S.E. (n=3 or 
4). (C) Cellular uptake of [3H]DHEAS (10 nM) in LNCaP cells was measured. LNCaP cells 
were cultured in RPMI1640 with 10% FBS (open, circle) or 10% CSS (closed) in the absence 
(circle) or the presence (square) of DHT (1 nM) for 2 days. Triangle symbols represent uptake 
of [3H]DHEAS (10 nM) in the presence of DHEAS (1 mM). Each bar represents the mean ± S.E. 
(n=3 or 4), and * indicates a significant difference from the uptake rate of [3H]DHEAS in 
LNCaP cells cultured with 10% CSS in the absence of DHEAS (1 mM) (p < 0.05) by Student’s 
t-test. 
 
Figure 4: Impact of OATP1A2-mediated DHEAS transport on proliferation of LNCaP cells. 
(A) Quantification of OATP1A2 mRNA expression in OATP1A2-knockdown (KD16 and 
KD34, closed bars) cells, compared with that in control (C3 and C9, open bars). Results are 
shown as the mean fold change (log2) ± S.E. Quantification of mRNA expression by qRT-PCR 
was repeated three times in duplicate. (B) Stimulatory effect of DHEAS on growth of 
OATP1A2-knockdown (open) and control cells (closed) in SRB assay. Cells were plated at 
8,000 cells in each well. The ratio of cell growth to that without DHEAS (5 μM) was calculated 
for C3 (circle), C9 (square), KD16 (circle), and KD34 (square) each day. Each value is the 
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